Cargando…

Early changes in gene expression profiles in AML patients during induction chemotherapy

BACKGROUND: Elucidation of the genetic mechanisms underlying treatment response to standard induction chemotherapy in AML patients is warranted, in order to aid in risk-adapted treatment decisions as novel treatments are emerging. In this pilot study, we explored the treatment-induced expression pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakobsen, Ingrid, Sundkvist, Max, Björn, Niclas, Gréen, Henrik, Lotfi, Kourosh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664790/ https://www.ncbi.nlm.nih.gov/pubmed/36376859 http://dx.doi.org/10.1186/s12864-022-08960-4

Ejemplares similares

Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin
por: Björn, Niclas, et al.
Publicado: (2020)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure
por: Åstrand, Anna, et al.
Publicado: (2020)

Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
por: Grundy, Martin, et al.
Publicado: (2018)

Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells
por: Rörby, Emma, et al.
Publicado: (2021)

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
por: Willander, Kerstin, et al.
Publicado: (2014)

Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2021)

G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
por: Osuorji, Ikenna, et al.
Publicado: (2012)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients
por: Bi, Yazhen, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

Gene Expression Profiles Associated with Pediatric Relapsed AML
por: Bachas, Costa, et al.
Publicado: (2015)

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
por: Schnell, Bianca R., et al.
Publicado: (2019)

Correction: Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients
por: Bi, Yazhen, et al.
Publicado: (2022)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

In Vitro Transformation of Primary Human CD34+ Cells by AML Fusion Oncogenes: Early Gene Expression Profiling Reveals Possible Drug Target in AML
por: Abdul-Nabi, Anmaar M., et al.
Publicado: (2010)

Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Early response evaluation in AML using mass cytometry
por: Gjertsen, Bjørn T., et al.
Publicado: (2019)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
por: Xu, Liangjing, et al.
Publicado: (2017)

Subclinical sympathetic neuropathy appears early in the course of Crohn's disease
por: Ohlsson, Bodil, et al.
Publicado: (2007)

Unique challenges to diagnosing sweet syndrome following induction chemotherapy for relapsed Acute Myeloid Leukemia (AML): A case and brief-review
por: Nazaretyan, Samvel, et al.
Publicado: (2023)

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
por: Dama, Paola, et al.
Publicado: (2019)

Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With AML
por: Bryant, Ashley Leak, et al.
Publicado: (2022)

P550: INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML
por: Abraham, Ivy, et al.
Publicado: (2023)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer
por: van Steenhoven, J. E. C., et al.
Publicado: (2019)

Proteomic Profiling Identifies Specific Leukemic Stem Cell-Associated Protein Expression Patterns in Pediatric AML Patients
por: Petersen, Marianne Agerlund, et al.
Publicado: (2022)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

An agonist antibody prefers relapsed AML for induction of cells that kill each other
por: Yea, Kyungmoo, et al.
Publicado: (2019)

DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy
por: Liu, Wei, et al.
Publicado: (2014)

Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy
por: Smith, Stephen M., et al.
Publicado: (2022)

Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
por: Vázquez-Blomquist, Dania, et al.
Publicado: (2023)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q5oqfcilhrveti683qbh2gkdmh